Endobronchial Valve for Emphysema PalliatioN Trial (VENT) Cost-effectiveness Sub-Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00137956|
Recruitment Status : Terminated
First Posted : August 30, 2005
Last Update Posted : August 18, 2009
|Condition or disease||Intervention/treatment||Phase|
|Emphysema Chronic Obstructive Pulmonary Disease||Device: Emphasys Endobronchial Valve (EBV) Device and Procedure||Phase 3|
Therapeutic interventions in health care require the use of resources. Since these resources are limited, it is important for clinical decision-makers to have economic information in addition to safety and efficacy data. In the economic environment of health care today, the incremental costs for a new therapeutic intervention must be offset by the value associated with better outcomes such as improved health and health-related quality of life and/or lower health care utilization costs over time.
Questions about the cost and effectiveness of medical care have generated considerable attention in medical outcomes research. In 1993, the Department of Health and Human Services appointed a multi-disciplinary group to recommend standards for the evaluation of health care. The panel's report suggested that standardized outcomes analyses be conducted to evaluate the cost-effectiveness of medical care. These analyses require preference-weighted measures of health-related quality of life. Such measures are needed in order to adjust survival time for health-related quality of life.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||270 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Endobronchial Valve for Emphysema PalliatioN Trial (VENT) Cost-effectiveness Sub-Study|
|Study Start Date :||December 2004|
- The cost-effectiveness ratio in the treatment group as compared to the control group at 180 days
- The cost-effectiveness ratio in the treatment group of the study will be compared to established therapies and standards.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00137956
|Principal Investigator:||Robert Kaplan, PhD||UCLA School of Public Health, UCSD Health Outcomes Assessment Program (HOAP)|